Detalhe da pesquisa
1.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980367
2.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
Br J Haematol
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38613141
3.
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
Breast Cancer Res Treat
; 203(2): 271-280, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37833451
4.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Lancet Oncol
; 24(10): 1073-1082, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666264
5.
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
Br J Haematol
; 203(3): 389-394, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37400251
6.
PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients.
Support Care Cancer
; 31(6): 337, 2023 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183206
7.
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Oncologist
; 27(3): e223-e232, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274723
8.
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
Breast Cancer Res Treat
; 194(1): 57-64, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35471470
9.
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
J Urol
; 207(5): 1010-1019, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35020444
10.
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
Oncologist
; 26(2): e316-e326, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33021006
11.
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Oncologist
; 26(7): 610-618, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604969
12.
A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
Breast Cancer Res Treat
; 186(1): 107-114, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33206291
13.
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Ann Allergy Asthma Immunol
; 126(6): 630-638, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33716146
14.
Immune-related cutaneous adverse events due to checkpoint inhibitors.
Ann Allergy Asthma Immunol
; 126(6): 613-622, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609771
15.
Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies.
J Am Acad Dermatol
; 85(3): 693-707, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781177
16.
Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.
J Am Acad Dermatol
; 84(2): 273-282, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171811
17.
Dermatologic infections in cancer patients treated with checkpoint inhibitors.
J Am Acad Dermatol
; 85(6): 1528-1536, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744355
18.
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
J Drugs Dermatol
; 20(9): 3ss-s19, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34491030
19.
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.
Oncologist
; 25(2): 140-149, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043775
20.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat
; 183(1): 227-237, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32613539